105494-69-7

Usage

Uses

Used in Pharmaceutical Industry:
1-Methyl-2-(tributylstannyl)-1H-imidazole is used as a drug candidate for its potential therapeutic applications. Its organostannic nature allows for the development of novel pharmaceutical agents with unique mechanisms of action, targeting various diseases and conditions.
Used in Drug Development:
As a drug candidate, 1-Methyl-2-(tributylstannyl)-1H-imidazole is utilized in the research and development of new medications. Its unique chemical structure offers opportunities for the design of innovative drugs with improved efficacy and reduced side effects.
Used as Ligand for Transition Metal Catalysts:
1-Methyl-2-(tributylstannyl)-1H-imidazole is employed as a ligand for transition metal catalysts, enhancing the performance of these catalysts in various chemical reactions. Its stannyl group provides a strong electron-donating effect, which can improve the catalytic activity and selectivity of the metal center.
Used in Molecular Functional Materials:
This organostannic compound is also used in the development of molecular functional materials, where its unique properties can be exploited to create materials with specific functions, such as sensing, energy storage, or optoelectronic applications.
Used in Proteomics Research:
1-Methyl-2-(tributylstannyl)-1H-imidazole is utilized in proteomics research as a valuable tool for the study of proteins and their interactions. Its organostannic nature allows for the selective labeling and detection of proteins, facilitating the identification and characterization of novel protein targets and pathways.

InChI:InChI=1/C4H5N2.3C4H9.Sn/c1-6-3-2-5-4-6;3*1-3-4-2;/h2-3H,1H3;3*1,3-4H2,2H3;/rC16H32N2Sn/c1-5-8-13-19(14-9-6-2,15-10-7-3)16-17-11-12-18(16)4/h11-12H,5-10,13-15H2,1-4H3

Upstream product

• 616-47-7 1-methyl-1H-imidazole 
• 1461-22-9 tributyltin chloride 

Downstream Products

• 385442-12-6 2-(4-fluorophenyl)-1-methyl-1H-imidazole 
• 641626-95-1 6-(1-methyl-1H-imidazol-2-yl)-3-(5-methyl-3-phenylisoxazol-4-yl)-2,4-dihydroindeno[1,2-c]pyrazole 
• 202196-76-7 (1-Benzyl-1H-indazol-5-yl)-(6-(1-methyl-1H-imidazol-2-yl)quinazolin-4-yl)-amine 
• 37148-90-6 1-methyl-2-(4-trifluoromethyl-phenyl)-1H-imidazole 
• 1446679-91-9 C₁₈H₁₈F₂N₄O₂ 
• 1431700-86-5 C₂₄H₂₅N₅O₂ 
• 1346815-71-1 3-{1-[5-fluoro-2-(1-methyl-1H-imidazol-2-yl)phenyl]ethoxy}-5-(2-methyl-2H-pyrazol-3-yl)pyridin-2-amine 
• 1138035-00-3 tert-butyl methyl{[4-(1-methyl-1H-imidazol-2-yl)-5-(phenylsulfonyl)thiophen-2-yl]methyl}carbamate 

Relevant academic research and scientific papers

Ru(II) complexes of tetradentate ligands related to 2,9-Di(pyrid-2′- yl)-1,10-phenanthroline

A series of 1,10-phenanthrolines were prepared having additional ligating substituents at the 2,9-positions. These substituents were either a 4-substituted pyrid-2-yl, quinolin-2-yl, 1,8-naphthyrid-2-yl, N-methyl imidazo-2-yl, or N-methyl benzimidazo-2-yl group. Additionally, 3,6-di-(pyrid-2′-yl)-dipyrido[3,2-a:2′,3′-c]phenazine was prepared. All but two of these ligands coordinated Ru(II) in a tetradentate equatorial fashion with two 4-methylpyridines bound in the axial sites. An X-ray structure analysis of the diimidazoyl system indicates considerable distortion from square planar geometry in the equatorial plane. Previously reported variations in the axial ligand for such complexes appear to have a stronger effect on the electronic absorption and redox properties of the system than similar changes in the equatorial ligand. In the presence of excess Ce(IV) as a sacrificial oxidant at pH 1, all the systems examined catalyze the decomposition of water to generate oxygen. Turnover numbers are modest, ranging from 146 to 416.

p27 PROTEIN INDUCER

The present invention provides a p27 protein inducing agent comprising a compound represented by general formula (11) below or pharmaceutically acceptable salt thereof as an active ingredient: wherein G 1 , G 2 , G 3 and G 8 are each independently selected from -N= etc., Ring G 6 is selected from divalent aryl etc., A is selected from amino etc., G 4 is selected from oxygen etc., G 5 is selected from oxygen etc., G 7 is selected from -CH 2 - etc., and R 2 is selected from C 1-6 alkyl etc.

p27 PROTEIN INDUCER

The present invention provides a p27 protein inducing agent comprising a compound represented by general formula (11) below or pharmaceutically acceptable salt thereof as an active ingredient: wherein G1, G2, G3 and G8 are each independently selected from -N= etc., Ring G6 is selected from divalent aryl etc., A is selected from amino etc., G4 is selected from oxygen etc., G5 is selected from oxygen etc., G7 is selected from -CH2- etc., and R2 is selected from C1-6 alkyl etc.

NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY

The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Y1 and Y2 are selected from -N= etc., Y3 and Y4 are selected from -CH= etc., A is selected from sulfamide etc., R1 is selected from hydrogen etc., and R2 is selected from C1-6 alkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.

Organotin Biocides. XIII. C-Triorganostannylimidazoles, -benzoxazoles and -benzothiazoles

The synthesis, spectroscopic characterisation, and reactivity of a series of triorganotin imidazoles, benzothiazoles and benzoxazoles R3Sn(Het) (R=Me, Bu, Ph) are described.The structure of 2-(triphenylstannyl)benzothiazole has been determined by crystallographic methods.Space group: Triclinic, P1; a 9.501(1), b 10.172(2), c 13.231(2) Angstroem, β 70.46(1), γ 69.71(1) deg, U 1082.8 Angstroem3, F(000)=484, μ(Mo-Kα) 11.74 cm-1, R=0.0719 for 2264 reflections with I>3?I.The geometry at the tin is tetrahedral.Bond angles at tin are used to discuss the reactivity and Moessbauer spectra of these species.